Unknown

Dataset Information

0

Ustekinumab in Crohn's disease: evidence to date and place in therapy.

ABSTRACT: Crohn's disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending.

SUBMITTER: Engel T 

PROVIDER: S-EPMC4935835 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Ustekinumab in Crohn's disease: evidence to date and place in therapy.

Engel Tal T   Kopylov Uri U  

Therapeutic advances in chronic disease 20160706 4

Crohn's disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional  ...[more]

Similar Datasets

Unknown Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
| S-EPMC5113936 | biostudies-other
Unknown Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy.
| S-EPMC6041873 | biostudies-literature
Transcriptomics Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
2022-11-08 | GSE207465 | GEO
Transcriptomics Transcriptomic profiling predicting response to ustekinumab therapy in patients with Crohn's disease
2023-10-31 | E-MTAB-7799 | biostudies-arrayexpress
Unknown Nintedanib in NSCLC: evidence to date and place in therapy.
| S-EPMC4872248 | biostudies-literature
Unknown Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy.
| S-EPMC4872251 | biostudies-literature
Unknown Clinical utility of ustekinumab in Crohn's disease.
| S-EPMC5810512 | biostudies-literature
Unknown Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients.
| S-EPMC5850325 | biostudies-literature
Unknown Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
| S-EPMC6032827 | biostudies-literature
Unknown Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification.
| S-EPMC8314105 | biostudies-literature